Current challenges in treating MRSA: what are the options? - Wikidata - wikimedia - TriplyDB

Current challenges in treating MRSA: what are the options?

Current challenges in treating MRSA: what are the options?

http://www.wikidata.org/entity/Q37291338

about

Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies.Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus.Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.Recurrent Challenges for Clinicians: Emergence of Methicillin-Resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options.Surveillance and management of multidrug-resistant microorganisms.Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

P2860

Q33472890-3D1C1B1D-5C85-444E-8389-3867335E5DA0 Q33529977-C9187E50-A205-4365-B41E-DD6FA6ED8EDB Q34737606-E26534AC-8DE4-4494-8BBE-34F8AF9898E2 Q35005092-0F79AE98-6535-4398-A214-8E16DF7AE897 Q37670551-C2547FCF-403A-4D41-B61B-62854ECF2ED4 Q37912231-BCABB0FD-31D6-4194-BAE0-21FC167F6531 Q41881874-6DC9C2ED-ABDF-4263-99FB-49B2063F492C Q42111513-39E2BE0F-4828-4C24-8BEB-56D9EE33864A

P2860

Current challenges in treating MRSA: what are the options?

http://www.wikidata.org/entity/Q37291338

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Current challenges in treating MRSA: what are the options?

@en

Current challenges in treating MRSA: what are the options?

@nl

type

label

Current challenges in treating MRSA: what are the options?

@en

Current challenges in treating MRSA: what are the options?

@nl

prefLabel

Current challenges in treating MRSA: what are the options?

@en

Current challenges in treating MRSA: what are the options?

@nl

P1433

Q37291338-1C65377C-A62C-4E51-BB97-7EA62ED1BABC

P1476

Q37291338-994245BD-C0C3-4811-9E64-9588F53B9F63

P2093

Q37291338-692B6786-19FB-49FC-940E-541F721D5BDC

Q37291338-E33FEE7F-5E7D-41AC-887F-BBDC7FE99202

P2860

Q37291338-00FE1CA9-D757-4CAC-8718-52BC3D1BE221

Q37291338-01ACE94F-FAB0-41BA-B1EB-6E694B070C5E

Q37291338-04711D7C-1AA9-4A58-9BE9-B5284D73A3DE

Q37291338-05603651-E469-42D3-98E8-62797A4363E6

Q37291338-05F17A7F-D84F-4C65-94F2-501F9437742C

Q37291338-07D98A4D-2447-4691-9438-1529B9B565F3

Q37291338-0F8EAF26-9FA2-4B25-B611-EEB95724C36E

Q37291338-0F93CAC5-ED37-4BB4-A852-6EE8ABE2460D

Q37291338-0FEC54FD-EC97-4F8E-8FC7-50F76E06938F

Q37291338-1008F86D-9288-4302-AC31-8075CB120DA6

P304

Q37291338-56CCD86D-D23B-44C6-A0C0-0083AF9CE06F

P31

Q37291338-0461260C-CA96-48B6-9A72-1FB930ADFB17

P356

Q37291338-6960B38B-F95B-46A8-AB7B-444491CE1642

P433

Q37291338-BB4E841B-4B6F-4BB2-AFBE-54DAC8DEAC52

P478

Q37291338-780C975D-E1D4-4CBF-89F6-D9FE49405225

P577

Q37291338-CCBED381-C94A-47C6-9023-18F3981D0C25

P5875

Q37291338-6E9BED2E-2C04-4354-A604-D8F453C36B7B

P698

Q37291338-E6A9F584-3343-429A-97D5-496F628E0F81

P356

14787210.6.5.601

P1433

Expert Review of Anti-infective Therapy

P1476

Current challenges in treating MRSA: what are the options?

@en

P2093

Natasha V D V Ratnaraja

http://www.w3.org/2001/XMLSchema#string

Peter M Hawkey

http://www.w3.org/2001/XMLSchema#string

P2860

Registered and Investigational Drugs for the Treatment of Methicillin-Resistant Staphylococcus aureus Infection

Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

Tigecycline: what is it, and where should it be used?

Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus

Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification.

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements.

Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus.

P304

601-618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.6.5.601

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23312846

http://www.w3.org/2001/XMLSchema#string

P698

18847401

http://www.w3.org/2001/XMLSchema#string